Want to know more about the 2019 HFTX Master Classes?
Visit our 2019 HFTX Master Class page for schedules, programs, registration information and more.

Want to know more about the 2019 HFTX Master Classes?
Visit our 2019 HFTX Master Class page for schedules, programs, registration information and more.

Visit the ISHLT2019 Online Program Viewer to see the full details for this session

Primary Audience: HF/HTX
Secondary Audience: MCS

Session Summary: The incidence of cardiogenic shock is increasing, leading to an emerging focus on refining our approach to shock. This symposium will provide a framework for understanding goals of treatment, defining phenotypes and profiles of shock, exploring geographical differences in management, and reviewing trends in use of temporary MCS.

Chairs: Teresa De Marco, MD and Richard Cheng, MD
 

10:30 AM	CASE PRESENTATION: ‘Gimme Gimme Shock Treatment’: Acute Cardiogenic Shock Patient Transferred for Advanced Heart Failure Therapy Adriana Torres, MD, LosCobos Medical Center, Bogota, Colombia
10:35 AM	DEBATE 1: ‘Culture Shock’: Tissue Perfusion is More Important than Hemodynamics in Managing Cardiogenic Shock (PRO) Daniel J. Goldstein, MD, Montefiore Medical Center, Bronx, NY, USA
10:50 AM	DEBATE 1: ‘Culture Shock’: Tissue Perfusion is More Important than Hemodynamics in Managing Cardiogenic Shock (CON) Jennifer Cowger, MD, MS, Henry Ford Hospitals, Detroit, MI, USA
11:05 AM	DEBATE 2: ‘Shock Rock’: One Treatment Fits All in Cardiogenic Shock (PRO) Shelley Hall, MD, Baylor University Medical Center, Dallas, TX, USA
11:20 AM	DEBATE 2: ‘Shock Rock’: One Treatment Fits All in Cardiogenic Shock (CON) Rebecca Cogswell, MD, University of Minnesota, Minneapolis, MN, USA
11:35 AM	DEBATE 3: ‘Shock Treatment’: All Patients Should Receive Temporary MCS in Cardiogenic Shock to Maximize Survival (PRO) Pascal Leprince MD, Hôpital de La Petie Salpetriere, Paris, France
11:50 AM	DEBATE 3: ‘Shock Treatment’: All Patients Should Receive Temporary MCS in Cardiogenic Shock to Maximize Survival (CON) David A. Baran, MD, Sentara Heart Hospital, Norfolk, VA, USA
12:05 PM	10-min Panel Discussion

Visit the ISHLT2019 Online Program Viewer to see the full abstracts from this session

Primary Audience: HF/HTX
Secondary Audience: EEP, ID, PATH

Chairs: Are M. Holm, MD, PhD, Howard Eisen, MD and Victor Rossel, MD
 

12:45 PM	(33) Sequential Measurement of Trypanosoma cruzi Parasitic Load in Endomyocardial Biopsies for Early Detection and Follow-up of Chagas Disease Reactivation After Heart Transplantation L. A. Benvenuti1, A. Roggério1, A. S. Nishiya2, S. Mangini1, J. E. Levi2. 1Heart Institute (InCor), Hospital das Clínicas da FMUSP, São Paulo, Brazil, 2Fundação Pró-Sangue, Hospital das Clínicas da FMUSP, São Paulo, Brazil
12:57 PM	(34) The Paradigm of Gender: Mismatch and Its Influence on Short and Long-Term Outcomes after Heart Transplantation M. D. Gilbert1, P. A. Morejón2, M. F. Renedo2, E. F. Giordanino2, L. E. Favaloro2, R. D. Ratto2, D. O. Absi1, R. R. Favaloro1, A. M. Bertolotti1. 1Cardiovascular, Thoracic Surgery, and Intrathoracic Transplantation, Hospital Universitario Fundación Favaloro, Buenos Aires, Argentina, 2Heart Failure and Heart Transplantation, Hospital Universitario Fundación Favaloro, Buenos Aires, Argentina
1:09 PM	(35) Incidence of Right Ventricular Dysfunction in Adult Patients Submitted to Heart Transplantation According to the Presence of Pre-Transplant Pulmonary Hypertension M. M. Lensi, A. S. Ramos, J. Xavier Junior, L. B. Seguro, S. Mangini, M. S. Ávila, I. W. Campos, A. P. Duque, F. Gaiotto, S. P. Steffen, F. Bacal, F. G. Marcondes-Braga. Heart Transplant Department, Heart Institute - InCor HC FMUSP, São Paulo, Brazil
1:21 PM	(36) The Effect of Donor-Recipient Heart Mass and Size Matching in Primary Graft Dysfunction Development after Heart Transplantation M. D. Gilbert1, P. A. Morejón2, M. F. Renedo2, E. F. Giordanino2, L. E. Favaloro2, R. D. Ratto2, D. O. Absi1, R. R. Favaloro1, A. M. Bertolotti1. 1Cardiovascular, Thoracic Surgery, and Intrathoracic Transplantation, Hospital Universitario Fundación Favaloro, Buenos Aires, Argentina, 2Heart Failure and Heart Transplantation, Hospital Universitario Fundación Favaloro, Buenos Aires, Argentina
1:33 PM	(37) Endomyocardial Biopsy after Heart Transplantation. When is Too Late? L. M. Guerrero Cepeda, F. G. Marcondes-Braga, D. M. Costa, R. M. Mendes, S. Duarte, J. C. Oliveira, I. Wosniack, L. F. Seguro, S. Mangini, F. Gaiotto, R. H. Santos, M. S. Avila, F. Bacal. Heart Transplantion, Instituto do Coração INCOR, São Paulo, Brazil

Visit the ISHLT2019 Online Program Viewer to see the full abstracts from this session

Primary Audience: HF/HTX

Chairs: Victor Rossel, MD and Jamila Kremer, MD
 

2:00 PM	(38) Non Ischemic Heart Preservation — Results from the Safety Study J. Nilsson1, V. Jernryd2, G. Qin3, A. Paskevicius3, T. Sjöberg3, P. Höglund4, S. Steen3. 1Skanes University Hospital Cardiothoracic Surgery, Lund, Sweden, 2Clinical Sciences Lund, Cardiothoracic Surgery, Lund University, Skane University Hospital, Lund, Sweden, 3Clinical Sciences Lund, Cardiothoracic Surgery, Lund University and Skane University Hospital, Lund, Sweden, 4Laboratory Medicine, Lund, Clinical Chemistry and Pharmacology, Lund University and Skane University Hospital, Lund, Sweden
2:15 PM	(39) Donation after Circulatory Death in Heart Transplantation May Increase the Donor Pool by 20% in the U.S O. K. Jawitz1, V. Raman1, A. Devore2, R. Mentz2, C. B. Patel2, M. Hartwig1, M. Daneshmand1, J. Schroder1, C. Milano1. 1Department of Surgery, Duke University School of Medicine, Durham, NC, 2Department of Medicine, Duke University School of Medicine, Durham, NC
2:30 PM	(40) DCD Donor Hearts Recipients Compared to DBD Donor Heart Recipients Present with Comparable Systolic Left Ventricular Function and Better Myocardial Strain at 1 Year Follow Up A. Ciarka1, A. Page2, S. Messer2, E. Pavlushkov2, S. Colah2, R. Axell2, B. Parizkova2, S. Tsui2, J. Parameshwar2, S. Large2. 1Cardiovascular Diseases, Catholic University of Leuven, Leuven, Belgium, 2of Transplantation, Papworth Hospital, NHS Foundation Trust, Cambridge, United Kingdom
2:45 PM	(41) A Data-Driven Framework for Monitoring and Improving Organ Donation Awareness among Minorities Using Optimal Social Network Intervention D. Pinheiro1, M. Murphy2, R. Iyengar2, J. Lazareff3, J. Choi4, R. Menezes5, M. Cadeiras1. 1Department of Internal Medicine, University of California, Davis, Sacramento, CA, 2Department of Medicine, University of California, Los Angeles, Los Angeles, CA, 3Center for World Health, University of California, Los Angeles, Los Angeles, CA, 4Department of Sociology, State University of San Diego, San Diego, CA, 5Department of Computer Science, University of California, Davis, Exeter, United Kingdom
3:00 PM	(42) The Impact of DCD Heart Transplantation on the Waiting List: A Single Centre Experience A. Page, R. Duehmke, S. Messer, S. Barra, M. Berman, S. Bhagra, J. Parameshwar, S. Tsui, P. Catarino, S. Pettit, S. Large. Papworth Hospital NHS Foundation Trust, Cambridge, United Kingdom
3:15 PM	(43) The Benefit of Heart Transplant Among Candidates Assigned Lower Priority in the New 6-Status US Heart Allocation System W. F. Parker1, E. S. Huang1, R. D. Gibbons2, A. S. Anderson3, M. M. Churpek1. 1University of Chicago Medicine, Chicago, IL, 2Public Health Sciences, University of Chicago Medicine, Chicago, IL, 3Northwestern Medicine, Chicago, IL
3:30 PM	(44) Clinical Factors Associated with Left Ventricular Recovery in Brain Dead Cardiac Donors J. R. Peacock, J. Ji, A. Bhatia, J. C. Hartupee, G. A. Ewald. Washington University in St. Louis, St. Louis, MO

Visit the ISHLT2019 Online Program Viewer to see the full abstracts from this session

Primary Audience: HF/HTX

Chairs: Luanda P. Grazette, MD and Maryl R. Johnson, MD
 

4:15 PM	(79) Successful Utilization of Extended Criteria Donor (ECD) Hearts for Transplantation - Results of the OCS™ Heart EXPAND Trial to Evaluate the Effectiveness and Safety of the OCS Heart System to Preserve and Assess ECD Hearts for Transplantation J. N. Schroder1, D. D'Alessandro2, F. Esmailian3, T. Boeve4, P. Tang5, K. Liao6, I. Wang7, A. Anyanwu8, A. Shah9, K. Mudy10, E. Soltesz11, J. W. Smith12. 1Duke University Medical Center, Durham, NC, 2Massachusetts General Hospital, Boston, MA, 3Cedars-Sinai Medical Center, Los Angeles, CA, 4Spectrum Health, Grand Rapids, MI, 5University of Michigan, Ann Arbor, MI, 6University of Minnesota, Minneapolis, MN, 7Indiana University, Indianapolis, IN, 8Mount Sinai, New York, NY, 9Vanderbilt University, Nashville, TN, 10Minneapolis Heart Institute, Minneapolis, MN, 11Cleveland Clinic Foundation, Cleveland, OH, 12University of Washington, Seattle, WA
4:30 PM	(80) Ex-vivo Perfusion on Marginal Donors in Heart Transplantation: Clinical Resuts and Pathological Findings S. Sponga1, V. Ferrara1, A. P. Beltrami2, A. Bonetti2, C. Cantarutti2, A. Caragnano2, F. Ortolani2, A. Lechiancole1, R. Esposito1, C. Di Nora1, V. Tursi3, C. Nalli1, U. Livi1. 1Cardiothoracic Department, Udine University Hospital, Udine, Italy, 2Medical Area Department (DAME), Udine University Hospital, Udine, Italy, 3Udine University Hospital, Udine, Italy
4:45 PM	(81) First to 50: Early Outcomes Following Heart Transplantation at Royal Papworth Hospital from Donation after Circulatory Determined Death (DCD) Donors S. Messer, A. Page, M. Berman, S. Colah, J. Dunning, E. Pavlushkov, P. Kaul, J. Parameshwar, Y. Abu-Omar, S. Pettit, C. Lewis, A. Kydd, S. Bhagra, A. Cockell, R. Quigley, J. Baxter, C. Ellis, D. Jenkins, C. Sudarshan, A. Ali, S. Tsui, P. Catarino, S. Large. Transplant Surgery, Royal Papworth Hospital, Cambridgeshire, United Kingdom
5:00 PM	(82) Cardiac Transplantation in Higher Risk Patients: Is Ex Vivo Heart Perfusion a Safe Preservation Technique? A Two Center Experience S. V. Rojas1, F. Ius1, D. Schibilsky2, T. Kaufeld1, W. Sommer1, C. Benk2, T. Goecke1, T. Siemeni1, R. Poyanmehr1, S. Rümke1, A. Mogaldea1, D. Bobylev1, J. Salman1, M. Avsar1, I. Tudorache1, C. Bara1, F. Beyersdorf2, A. Haverich1, M. Siepe2, G. Warnecke1. 1Department of Cardiothoracic-, Transplantation- and Vascular Surgery, Hannover Medical School, Hannover, Germany, 2Department of Thoracic and Cardiovascular Surgery, University of Freiburg, Freiburg, Germany
5:15 PM	(83) Keeping It Cool: Extended Myocardial Protection with Topical Cooling to Reduce PGD S. Avtaar Singh1, S. Das De1, K. Morcos1, Y. Hegazy1, H. Al-Haideri1, S. Nair1, J. Dalzell2, H. Doshi1, N. Al-Attar1, P. Curry1. 1Cardiothoracic Surgery, Golden Jubilee National Hospital, Glasgow, United Kingdom, 2Scottish National Advanced Heart Failure Service, Golden Jubilee National Hospital, Glasgow, United Kingdom
5:30 PM	(84) The First Clinical Use of a Novel Cold Storage System of Donor Hearts N. Naito1, M. Funamoto1, R. Pierson1, M. Villavicencio1, W. Riley2, G. Lewis3, D. D'Alessandro1. 1Cardiac Surgery, Massachusetts General Hospital, Boston, MA, 2Perfusion Services, Massachusetts General Hospital, Boston, MA, 3Cardiology, Massachusetts General Hospital, Boston, MA
5:45 PM	(85) Heart Ablation Avoiding Asystolia with an Always- Beating Heart I. G. Berra1, M. L. Berra2, M. A. Lewis3, S. Berra4, A. O. Irusta5, G. Berra6, P. A. Takeuchi5. 1Heart, Lung and Kidney Transplant Team, Hospital Nacional de Pediatría JP Garrahan, Moron, Argentina, 2Clinica Medica, Hospital Nacional Alejandro Posadas, Morón, Argentina, 3Vice President, Lew Insumos e Innovaciones, Moron, Argentina, 4Facultad de Ingeniería, Universidad de Buenos Aires, Buenos Aires, Argentina, 5Design Team, Lew Insumos e Innovaciones, Moron, Argentina, 6President, Lew Insumos e Innovaciones, Moron, Argentina

Visit the ISHLT2019 Online Program Viewer to see the full abstracts from this session

Heart Transplantation (Adult) (Timor Sea 1)
(HTX)   Poster Numbers: 687-737
 

---

Visit the ISHLT2019 Online Program Viewer to see the full abstracts from this session

Heart Transplantation (Adult) (Timor Sea 2)
(HTX)   Poster Numbers: 643-686

Visit the ISHLT2019 Online Program Viewer to see the full abstracts from this session

Primary Audience: HF/HTX
Secondary Audience: MCS

Chairs: Steven SL Tsui, MD, FRCS and Alanna A. Morris, MD
 

6:15 PM	(369) How Big is Too Big? An Analysis of Morbidly Obese Heart Donors in the UNOS Database E. D. Krebs, J. P. Beller, J. H. Mehaffey, N. R. Teman, J. L. Kennedy, G. Ailawadi, L. T. Yarboro. University of Virginia, Charlottesville, VA
6:20 PM	(370) Label-Free Proteomics Approach Characterizes Plasma Protein Signature of Donor Brain Death J. Lukac1, M. Saraswata2, S. Joenvääräa2, E. Holmström1, K. Dhaygude3, R. Krebs1, A. Nykänen1, R. Renkonen2, K. Lemström1. 1Cardiopulmonary Research Group, Transplantation Laboratory University of Helsinki, Helsinki, Finland, 2Mass Spectrometry Group, Transplantation Laboratory University of Helsinki, Helsinki, Finland, 3Cardiovascular Research Group, Transplantation Laboratory, University of Helsinki, Helsinki, Finland
6:25 PM	(371) Donor Hormonal Thyroid Therapy is Associated with Increased Risk of Primary Graft Dysfunction after Heart Transplantation Y. Peled, J. Lavee, E. Nachum, Y. Kassif, M. Arad, A. Kogan, D. Freimark, E. Ram. Sheba Medical Center Tel Hashomer and Tel-Aviv University, Ramat Gan, Israel
6:30 PM	(372) Matchmaking Just Got Easier: Impact of Phenotypic Donor-Recipient Likeness in Open Heart Transplantation B. D. Lo, A. Suarez-Pierre, X. Zhou, C. Lui, M. F. Hunt, G. J. Whitman, C. W. Choi, A. Kilic. Division of Cardiac Surgery, The Johns Hopkins University School of Medicine, Baltimore, MD
6:35 PM	(373) Oversizing Donors - Is It Necessary for ACHD Patients?: An Analysis of the United Network for Organ Sharing Registry D. E. Clark1, R. D. Byrne2, D. S. Burnstein3, M. R. Danter4, R. Fowler1, B. P. Frischhertz1, J. Lindenfeld1, J. A. Mazurek5, B. A. Mettler6, A. Opotowsky7, T. L. Richardson2, E. M. Sandhuas1, K. H. Schlendorf1, J. Schmeckpeper1, A. S. Shah4, A. J. Weingarten8, S. Zalawadiya1, J. N. Menachem1. 1Cardiovascular Medicine, Vanderbilt University Medical Center, Nashville, TN, 2Internal Medicine-Pediatrics, Vanderbilt University Medical Center, Nashville, TN, 3Cardiology, Children's Hospital of Philadelphia, Philadelphia, PA, 4Cardiac Surgery, Vanderbilt University Medical Center, Nashville, TN, 5Cardiovascular Medicine, University of Pennsylvania, Philadelphia, PA, 6Pediatric Cardiac Surgery, Vanderbilt University Medical Center, Nashville, TN, 7Cardiology, Harvard Medical School, Boston, MA, 8Cardiovascular Medicine, Vanderbilt University, Nashville, TN
6:40 PM	(374) Mitigating the Impact of Gender Mismatch in Heart Transplantation Using BMI and BSA Ratios Y. D. Barac, O. Jawitz, V. Raman, M. Hartwig, J. Klapper, J. Schroder, M. Daneshmand, C. Patel, C. Milano. Duke University Medical Center, Durham, NC
6:45 PM	(375) Characteristics and Short-Term Outcomes of Hepatitis C Antibody Positive Organs for Heart Transplantation: UNOS Analysis E. M. DeFilippis, R. C. Givens, A. R. Garan, F. Latif, S. W. Restaino, Y. Naka, K. Takeda, H. Takayama, P. C. Colombo, M. A. Farr, V. K. Topkara. Columbia University Medical Center, New York, NY
6:50 PM	(376) Heart Transplant Recipient and Donor Age: Should the Younger Recipient Be Matched with the Younger Donor? Y. Ravi1, N. Srikanth2, I. W. Paul3, B. A. Whitson4, S. Emani5, C. B. Sai-Sudhakar1. 1Cardiac Surgery, Scott & White, Texas A&M, Temple, TX, 2Medical Student, Saveetha Institute of Medical Sciences, Chennai, India, 3Medical Student, Sree Mookambika Institute of Medical Sciences, Kulasekaram, India, 4Cardiac Surgery, The Ohio State University, Columbus, OH, 5Internal Medicine, The Ohio State University, Columbus, OH
6:55 PM	(377) Impact of Donor to Recipient Size Match on Survival after Heart Transplant Bridged with Continuous Flow Left Ventricular Assist Device R. Yanagida1, A. Okoh2, S. Fugar3, M. Camacho4, M. Strueber4, M. J. Zucker2. 1Newark Beth Israel Medical Center, Newark, NJ, 2Department of Medicine, Newark Beth Israel Medical Center, Newark, NJ, 3Department of Medicine, Rush University Medical Center, Chicago, IL, 4Department of Cardiothoracic Surgery, Newark Beth Israel Medical Center, Newark, NJ
7:00 PM	(378) Older Donors Portend Worse Survival in Older and Younger Recipients after Heart Transplant: A UNOS Database Analysis V. Raman, O. K. Jawitz, C. White, M. Daneshmand, J. Schroder, C. Milano, M. Hartwig. Duke University Medical Center, Durham, NC
7:05 PM	(379) Cardiac Allografts from Overdosed Donors: An Underutilized Resource? N. K. Ranganath1, K. G. Phillips1, J. Malas1, B. E. Lonze2, D. E. Smith1, Z. N. Kon1, C. G. Gidea3, A. Reyentovich3, N. Moazami1. 1Cardiothoracic Surgery, NYU Langone Health, New York, NY, 2Surgery, NYU Langone Health, New York, NY, 3Medicine, NYU Langone Health, New York, NY
7:10 PM	(380) Donors after Circulatory Death at the Medical College of Wisconsin and Potential for Increased Volume in Cardiac Transplantation A. Cole1, A. Mohammed2, L. Durham1, N. Gaglianello2, D. Ishizawar2, L. Joyce1, R. Kursel2, M. Saltzberg2, D. Joyce1. 1Cardiothoracic Surgery, Medical College of Wisconsin, Milwaukee, WI, 2Advanced Heart Failure, Medical College of Wisconsin, Milwaukee, WI

Visit the ISHLT2019 Online Program Viewer to see the full details for this session

Primary Audience: HF/HTX

Session Summary: Hypertrophic and infiltrative cardiomyopathies are often underrecognized. There has been increasing understanding of HCM and cardiac amyloidosis with rapid development of diagnostic modalities and treatment strategies. This symposium will begin with a case and then review recent advances, highlighting key therapeutics that are available and being developed. The role of heart transplant and advanced therapies in these entities will be outlined.

Chairs: Jignesh K. Patel, MD, PhD and Marta Farrero Torres, MD
 

7:00 AM	CASE PRESENTATION of HCM: Gasping and Dizzy - Please Help! Imad Hussain, MD, Houston Methodist Hosp, Houston, TX, USA
7:05 AM	Veni, Vidi, Vici: Pathophysiology and Therapeutic Options in Hypertrophic Cardiomyopathy Eulalia Roig, MD, Hospital Sant Pau, Barcelona, Spain
7:25 AM	CASE PRESENTATION of Cardiac Amyloidosis: I Can't Breathe and My Tongue is Too Big! Song Li, MD, University of Washington, Seattle, WA, USA
7:30 AM	Double Double Toil and Trouble: Physiology and Therapeutic Options for Cardiac Amyloidosis Margot Davis, MD, University of British Columbia, Vancouver, BC, Canada
7:50 AM	10-min Panel Discussion

Visit the ISHLT2019 Online Program Viewer to see the full abstracts from this session

Primary Audience: HF/HTX
Secondary Audiences: ID

Chairs: JoAnn Lindenfeld, MD and Sandet Singh Avatar Singh, MRCS, MSc
 

8:00 AM	(93) Early Utilization Trends and Outcomes of Hepatitis C Donor Hearts in the Era of Nucleic Acid Amplification Testing (NAT) and Direct Acting Antivirals (DAAs) S. Madan, S. R. Patel, O. Saeed, S. Forest, J. J. Shin, D. B. Sims, D. J. Goldstein, U. P. Jorde. Montefiore Medical Center, Bronx, NY
8:15 AM	(94) Use of Donor HCV NAT Positive Hearts: Expanding the Donor Pool? E. C. DePasquale1, C. J. Lum1, R. Chand1, W. Ragalie1, A. Chang1, A. Salimbangon1, M. Deng1, M. Cadeiras2, T. Khuu1, D. Vucicevic3, K. Pandya4, A. Ardehali1. 1UCLA, Los Angeles, CA, 2UC Davis, Sacramento, CA, 3Newark Beth Israel, Newark, NJ, 4USC, Los Angeles, CA
8:30 AM	(95) Clinical Experience with Heart Transplantation from Hepatitis C Positive Donors A. Reyentovich1, C. Gidea1, D. Smith2, B. Lonze3, J. Pavone1, S. Katz1, S. Pan1, S. Rao1, T. Saraon1, N. Moazami4. 1Heart Transplant, NYU Langone Medical Center, New York, NY, 2CardioThoracic Surgery, NYU Langone Medical Center, New York, NY, 3Transplant Surgery, NYU Langone Medical Center, New York, NY, 4Cardiothoracic Surgery, NYU Langone Medical Center, New York, NY
8:45 AM	(96) Successful Transplantation of 58 Hepatitis C-Exposed Donor Hearts in the Era of Direct-Acting Antiviral Therapies K. Schlendorf, S. Zalawadiya, A. Shah, M. Wigger, R. Perri, M. Danter, M. Brinkley, J. Menachem, S. Brown Sacks, H. Ooi, L. Punnoose, K. Balsara, L. Stevenson, J. Awad, R. Fowler, H. O'dell, S. Ruzevich-Scholl, J. Lindenfeld. Vanderbilt University Medical Center, Nashville, TN
9:00 AM	(97) Regional Variation in Utilization of Hepatitis C-Positive Organs for Heart Transplantation in the United States E. M. DeFilippis1, A. R. Garan1, R. C. Givens1, L. K. Truby2, F. Latif1, S. W. Restaino1, K. Takeda1, H. Takayama1, Y. Naka1, P. C. Colombo1, M. A. Farr1, V. K. Topkara1. 1Columbia University Medical Center, New York, NY, 2Duke University Medical Center, Durham, NC
9:15 AM	(98) Trends in Renal Function among Heart-Transplant Recipients of Donor-Derived Hepatitis C Virus S. Zalawadiya1, J. Lindenfeld1, A. Shah2, M. Wigger1, M. Danter2, D. Brinkley1, J. Menachem1, L. Punnoose1, S. Brown Sacks1, H. Ooi1, K. Balsara2, R. Perri3, J. Awad3, S. Smith1, R. Fowler1, H. O'Dell3, C. Darragh3, S. Ruzevich-Scholl1, K. Schlendorf1. 1Heart Failure and Transplantation, Vanderbilt University Medical Center, Nashville, TN, 2Cardiac Surgery, Vanderbilt University Medical Center, Nashville, TN, 3Gastroenterology and Hepatology, Vanderbilt University Medical Center, Nashville, TN
9:30 AM	(99) Acceptance of HCV-Positive Donor Hearts Improves Organ Acceptance Selectivity: Single Center Experience K. J. Gaj1, D. A. D'Alessandro2, E. D. Bethea3, J. L. Gustafson3, M. A. Villavicencio-Theoduloz2, R. T. Chung3, G. D. Lewis4. 1Cardiac Transplantation, Massachusetts General Hospital, Boston, MA, 2Cardiothoracic Surgery, Massachusetts General Hospital, Boston, MA, 3Liver Center and Gastrointestinal Division, Massachusetts General Hospital, Boston, MA, 4Advanced Heart Disease, Massachusetts General Hospital, Boston, MA

Visit the ISHLT2019 Online Program Viewer to see the full abstracts from this session

Primary Audience: HF/HTX
Secondary Audiences: BSTR, PATH

Chairs: Pradeep P.A. Mammen, MD, FACC, FAHA and Markus Johannes Barten, MD, PhD
 

8:00 AM	(100) Increase in Donor Fraction Cell-Free DNA Correlates with Cellular and Antibody Mediated Rejection (ACR/AMR) in Adult and Pediatric Heart Transplant Recipients: DNA Based Transplant Rejection Test (DTRT)-A Prospective Blinded Multicenter NIH/NHLBI Funded Clinical Study M. E. Richmond1, S. J. Kindel2, J. N. Schroder3, S. R. Deshpande4, D. P. Bichell5, M. A. Wigger6, K. R. Knecht7, E. Pahl8, N. A. Gaglianello9, P. M. Simpson10, W. T. Mahle11, A. T. Mitchell12, S. D. Zangwill13, M. E. Mitchell14. 1Pediatrics, Columbia University, New York, NY, 2Pediatrics, Children's Hospital of Wisconsin, Milwaukee, WI, 3Surgery, Duke University, Durham, NC, 4Children's National, Washington, DC, 5Surgery, Vanderbilt University, Nashville, TN, 6Medicine, Vanderbilt University, Nashville, TN, 7Pediatrics, Arkansas Children's Hospital, Little Rock, AR, 8Pediatrics, Ann & Robert H. Lurie Children's Hospital, Chicago, IL, 9Medicine, Medical College of Wisconsin, Milwaukee, WI, 10Pediatrics, Medical College of Wisconsin, Milwaukee, WI, 11Emory University, Atlanta, GA, 12Surgery and Biomedical Engineering, Medical College of Wisconsin and Children's Hospital of Wisconsin, Milwaukee, WI, 13Pediatrics, Phoenix Children's Hospital, Phoenix, AZ, 14Surgery, Pediatric Cardiothoracic Surgery, Children's Hospital of Wisconsin, Milwaukee, WI
8:15 AM	(101) Increase in Total Cell-Free DNA Correlates with Death in Adult and Pediatric Heart Transplant Recipients: DNA Based Transplant Rejection Test (DTRT)-A Prospective Blinded Multicenter NIH/NHLBI Funded Clinical Study S. D. Zangwill1, S. J. Kindel2, J. N. Schroder3, D. P. Bichell4, S. R. Deshpande5, M. A. Wigger6, M. E. Richmond7, K. R. Knecht8, N. A. Gaglianello9, E. Pahl10, P. M. Simpson11, W. T. Mahle12, A. T. Mitchell13, M. E. Mitchell14. 1Pediatrics, Phoenix Children's Hospital, Phoenix, AZ, 2Pediatrics, Children's Hospital of Wisconsin, Milwaukee, WI, 3Surgery, Duke University, Durham, NC, 4Surgery, Vanderbilt University, Nashville, TN, 5National Children's Hospital, Washington, DC, 6Medicine, Vanderbilt University, Nashville, TN, 7Pediatrics, Columbia University, New York, NY, 8Pediatrics, Arkansas Children's Hospital, Little Rock, AR, 9Medicine, Medical College of Wisconsin, Milwaukee, WI, 10Pediatrics, Ann & Robert H. Lurie Children's Hospital, Chicago, IL, 11Pediatrics, Medical College of Wisconsin, Milwaukee, WI, 12Pediatrics, Emory University, Atlanta, GA, 13Surgery, Medical College of Wisconsin and Children's Hospital of Wisconsin, Milwaukee, WI, 14Surgery, Pediatric Cardiothoracic Surgery, Medical College of Wisconsin and Children's Hospital of Wisconsin, Milwaukee, WI
8:30 AM	(102) Correlation of Human Myocardial Apoptosis with Pathology Rejection Grade and Levels of Donor-Derived Cell-Free DNA in Heart Transplantation S. Pattar1, F. Iqbal2, D. Isaac3, N. Fine3, S. C. Greenway4. 1Biochemistry & Molecular Biology, University of Calgary, Calgary, AB, Canada, 2Health Sciences, University of Calgary, Calgary, AB, Canada, 3Libin Cardiovascular Institute of Alberta, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, 4Pediatrics, Cardiac Sciences, Biochem.& Molecular Bio/Alberta Children's Hospital Research Institute, University of Calgary, Calgary, AB, Canada
8:45 AM	(103) Distinct Patterns of Gene Expression Identified Longitudinally and within AlloMap Score Ranges are Associated with Clinical Outcomes A. Loupy1, R. N. Woodward2, M. Machrus2, S. P. Pinney3, J. A. Kobashigawa4. 1Hospital Necker, Paris, France, 2CareDx, Brisbane, CA, 3Mt Sinai Health System, New York, NY, 4Cedars-Sinai Heart Institute, Los Angeles, CA
9:00 AM	(104) Molecular Microscope Determinants of Graft Survival in the INTERHEART Study J. Reeve1, D. H. Kim1, M. G. Crespo-Leiro2, J. Kobashigawa3, L. Potena4, M. Deng5, M. Cadeiras5, E. C. Depasquale5, A. Loupy6, P. Macdonald7, A. Zuckermann8, A. Z. Aliabadi8, J. Goekler8, M. Parkes1, P. F. Halloran1. 1University of Alberta, Edmonton, AB, Canada, 2Complexo Hospitalario Universitario A Coruña, A Coruña, Spain, 3Cedars-Sinai Medical Center, Los Angeles, CA, 4University of Bologna, Bologna, Italy, 5Ronald Reagan UCLA Medical Center, Los Angeles, CA, 6Hôpital Necker, Paris, France, 7The Victor Chang Cardiac Research Institute, Sydney, Australia, 8Medical University of Vienna, Vienna, Austria
9:15 AM	(105) miR-208a-5p and miR-135a-5p in Formalin Fixed Paraffin Embedded Endo-Myocardial Monitoring Biopsies Discriminate Rejection from Cardiac Infection A. Di Francesco1, M. Fedrigo1, C. Castellani1, D. Gregori1, D. Santovito2, L. Natarelli2, G. Toscano1, T. Bottio1, G. Thiene1, M. Valente1, M. Valente1, A. Schober2, C. Basso1, G. Gerosa1, A. Angelini1. 1Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova, Padova, Italy, 2Institute for Cardiovascular Prevention (IPEK), Ludwig-Maximillians University (LMU), Munich, Germany
9:30 AM	(106) Circulating, Cell-Free, MicroRNA Sequencing to Diagnose Cardiac Allograft Rejection and Distinguish Rejection Subtype P. Shah1, S. Agbor-Enoh2, W. Zhu3, M. Harpole3, Y. Wakabayashi4, K. Bhatti2, P. Kothiyal3, U. Fideli2, S. Hsu5, M. E. Rodrigo6, E. Feller7, K. B. Shah8, R. K. Iyer3, J. Zhu4, H. Valantine2. 1Heart Failure and Transplantation, Inova Heart and Vascular Institute, Falls Church, VA, 2National Heart, Lung and Blood Institute, Bethesda, MD, 3Inova Translational Medicine Institute, Falls Church, VA, 4Mokobio, Rockville, MD, 5Heart Failure and Transplantation, Johns Hopkins University, Baltimore, MD, 6Heart Failure and Transplantation, Washington Hospital Center, DC, DC, 7Heart Failure and Transplantation, University of Maryland, Baltimore, MD, 8Heart Failure and Transplantation, Virginia Commonwealth University, Richmond, VA

Visit the ISHLT2019 Online Program Viewer to see the full abstracts from this session

Primary Audience: HF/HTX
Secondary Audiences: NHSAH

Chairs: George G. Sokos, DO and Wandy Chan, PhD, FRACP
 

10:15 AM	(128) Genomic Prediction of One Year Survival Status Related to Functional Recovery Potential in Advanced Heart Failure Patients Undergoing Mechanical Circulatory Support G. Bondar1, T. Bao1, M. Kurani1, D. L. Bhaskar1, A. Le1, R. Dod1, Y. Khachatoorian1, A. Aliyari1, E. Higuchi1, E. Oh1, K. Patel1, M. Cadeiras2, J. Schaenman1, L. Masukawa1, S. Kupiec-Weglinski3, V. Groysberg1, M. Bakir1, E. Depasquale1, M. Kamath1, D. Liem1, J. Meltzer1, M. Kwon1, M. Rossetti1, D. Elashoff1, X. Li1, E. Reed1, P. Ping1, M. C. Deng1. 1David-Geffen Sch Med, Los Angeles, CA, 2University of California Davis School of Medicine, Sacramento, CA, 3Cornell University, Ithaca, NY
10:30 AM	(129) Impact of Frailty on Health-Related Quality of Life from before to 6 Months after Surgery: Findings from the Sustaining Quality of Life of the Aged: Transplant or Mechanical Support (SUSTAIN-IT) Study K. Ghafourian1, A. C. Andrei2, Y. Xu2, C. W. Yancy1, H. Adam2, D. T. Pham2, K. L. Grady2. 1Cardiology, Northwestern University, Chicago, IL, 2Surgery, Northwestern University, Chicago, IL
10:45 AM	(130) Leg Muscle Strength Independently Predicts Clinical Outcome in Patients with Acute Decompensated Heart Failure J. Youn1, E. Yoon1, H. Choi2, I. Kim3, J. Lee1, S. Lee1, S. Han1, S. Kang4. 1Dongtan Sacred Heart Hospital, Hallym University, Hwaseong, Korea, Republic of, 2Hallym University Sacred Heart Hospital, Anyang, Korea, Republic of, 3Keimyung University Dongsan Medical Center, Daegu, Korea, Republic of, 4Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Korea, Republic of
11:00 AM	(131) Comparison of Percutaneous Ventricular Assist Device and Intra-Aortic Balloon Pump for Cardiogenic Shock A. Y. Lee1, C. Y. Guerrero-Miranda1, T. Nisar2, A. K. Jamil2, A. Perez1, D. Tangellamundi1, J. Felius2, S. A. Hall1, D. Wencker1. 1Baylor University Medical Center, Dallas, TX, 2Baylor Scott & White Research Institute, Dallas, TX
11:15 AM	(132) Characteristics and Outcomes of Patients with Cardiogenic Shock Complicated by Acute Kidney Injury Requiring Hemodialysis C. Inampudi1, O. Adegbala2, E. Akintoye1, P. Alvarez1, A. Briasoulis1. 1Internal Medicine - Cardiology, Univ of Iowa Hospital, Iowa City, IA, 2Internal Medicine, Englewood Hospital and Medical Center, Seton Hall University-Hackensack Meridian School of Medicine, Englewood, New Jersey, NJ
11:30 AM	(133) LVAD Survival May Be Predicted by Preoperative Lymphopenia K. Stawiarski1, O. Agboola2, D. Jacoby3, L. Bellumkonda3, L. Sugeng3, T. Ahmad3, M. Chen3, G. McCloskey2, A. Geirsson2, M. Anwar2, P. Bonde2. 1Yale New Haven Health Bridgeport Hospital, Bridgeport, CT, 2Yale School of Medicine, New Haven, CT, 3Yale School of Medicine, Bridgeport, CT
11:45 AM	(134) Differences in Health-Related Quality of Life by Socio-Demographic Characteristics: Findings from the Sustaining Quality of Life of the Aged: Transplant or Mechanical Support (SUSTAIN-IT) Study L. Uppalapati1, A. Andrei2, C. Yancy3, Y. Xu2, H. Adam2, D. Pham2, K. L. Grady2. 1Northwestern University, Chicago, IL, 2Surgery / Cardiac Surgery, Northwestern University, Chicago, IL, 3Medicine, Northwestern University, Chicago, IL

Visit the ISHLT2019 Online Program Viewer to see the full abstracts from this session

Primary Audience: HF/HTX
Secondary Audience: ID, PHARM

Chairs: Darko Vucicevic, MD and Monica Colvin, MD
 

1:45 PM	(161) Late-Breaking Clinical Trial: 10-Year Follow-Up of the Everolimus versus Azathioprine Multi-National Study J. A. Kobashigawa1, R. Starling2, E. Passano1, P. Bernhardt3, B. Azarbal1, R. Cheng1, F. Esmailian1, K. Khush4, D. Mancini5, J. Patel1, T. Sato1, S. Varnous6. 1Smidt Heart Institute at Cedars-Sinai, Los Angeles, CA, 2Cleveland Clinic, Cleveland, OH, 3Novartis Pharmaceuticals, Basel, Switzerland, 4Stanford University, Palo Alto, CA, 5Mount Sinai, New York, NY, 6APHP, Pitié‐Salpétrière, Sorbonne University, Paris, France
2:00 PM	(162) Effect of Donor Simvastatin Treatment on Gene Expression Profiles in Human Cardiac Allografts during Ischemia-Reperfusion Injury R. Krebs1, M. Kankainen2, E. Holmström1, K. Dhaygude1, J. Lukac1, T. Ojala2, P. Mattila2, A. Nykänen1, K. Lemström1. 1Transplantation Laboratory, University of Helsinki, Helsinki, Finland, 2Institute for Molecular Medicine Finland, University of Helsinki, Helsinki, Finland
2:15 PM	(163) Higher Intensity Statin Therapy Reduces Clinical Endpoints after Heart Transplantation Independent of Lipid Levels J. R. Golbus1, S. Adie1, S. Hanigan1, M. Dorsch1, B. Rooks2, K. D. Aaronson1, M. C. Konerman1. 1Internal Medicine, University of Michigan, Ann Arbor, MI, 2University of Michigan, Ann Arbor, MI
2:30 PM	(164) Everolimus in the Prevention of Calcineurin-Inhibitor-Induced Left Ventricular Hypertrophy in Heart Transplantation (RAD-TAC Study) C. Anthony, M. Imran, S. Emmanuel, J. Iliff, E. Kotlyar, K. Muthiah, A. M. Keogh, C. S. Hayward, P. S. Macdonald, A. Jabbour. Heart and Lung Transplant, St Vincent's Hospital Sydney, Sydney, Australia
2:45 PM	(165) Gut Microbial Diversity, Inflammation and Oxidative Stress is Associated with Tacrolimus Dosing Requirements Early after Heart Transplant D. L. Jennings1, B. Bohn Damasceno Ferreira2, A. Zuver2, O. Drew3, M. Gaine3, E. Royzman3, J. Hupf3, M. Farr3, F. Latif3, S. Restaino3, A. R. Garan3, H. Takayama4, K. Takeda4, Y. Naka4, P. C. Colombo3, R. Demmer5, M. Yuzefpolskaya3. 1Pharmacy, NewYork-Presbyterian Hospital, New York, NY, 2Public Health, Columbia University, New York, NY, 3Medical Cardiology, Columbia University, New York, NY, 4Cardiothoracic Surgery, Columbia University, New York, NY, 5Public Health, University of Minnesota, Minneapolis, MN
3:00 PM	(166) Early Infection Risk Associated with Induction Immunosuppression after Cardiac Transplant in Patients with Left Ventricular Assist Devices J. Batra1, D. L. Jennings1, A. R. Garan1, L. K. Truby1, K. Takeda2, H. Takayama2, S. Restaino1, F. Latif1, J. Haythe1, M. Yuzefpolskaya1, P. C. Colombo1, Y. Naka2, M. A. Farr1, V. K. Topkara1. 1Medicine, Columbia University, New York, NY, 2Surgery, Columbia University, New York, NY
3:15 PM	(167) Specific Immune Tolerance Response Triggered by Extracorporal Photopheresis after Heart Transplantation K. Klaeske1, M. Dieterlen1, J. Wittke1, M. Borger1, J. Garbade1, S. Lehmann1, H. Reichenspurner2, M. Barten2. 1Clinic for Cardiac Surgery, Heart Center Leipzig, Leipzig, Germany, 2University Heart Center Hamburg, Hamburg, Germany

Visit the ISHLT2019 Online Program Viewer to see the full details for this session

Primary Audience: HF/HTX
Secondary Audiences: MCS, PEDS

Session Summary: The aim of this symposium is to describe the pathophysiology and management of heart failure syndromes that are unique to ACHD patients.

Chairs: Maryjane Farr, MD and Heather J. Ross, MD, MHSc, FRCPC
 

1:45 PM	Too Sick to Live, Too Well to Die: When Do You Transplant A Failing ACHD Patient? Daphne Hsu, MD, Children's Hospital Montefiore, Bronx, NY, USA
2:00 PM	Q&A
2:05 PM	Is Two Really Better Than One? Heart-Liver Transplantation in ACHD Clive J. Lewis, MB, BChir, PhD, FRCP, Papworth Hospital, Cambridge, United Kingdom
2:20PM	Q&A
2:25 PM	Under Pressure: Managing Pulmonary Hypertension in ACHD Robert Weintraub, MD, Royal Children's Hospital, Parkville, Australia
2:40PM	Q&A
2:45 PM	I've Got Options: VADs in Patients with ACHD David Morales, MD, Cincinnati Children's Hospital, Cincinnati, OH, USA
3:00 PM	Q&A
3:05 PM	The Failing Sub-Pulmonic RV in Congenital Heart Disease: Forgotten, But Not Gone Wendy M. Book, MD, Emory University, Atlanta, GA, USA
3:20 PM	Q&A

Visit the ISHLT2019 Online Program Viewer to see the full abstracts from this session

Primary Audience: HF/HTX
Secondary Audience: BSTR, PATH

Chairs: David Schibilsky, MD and Ravikumar Ratnagiri, MD
 

4:00 PM	(189) Clinical and Pathological Insights of Myocardial Molecular Profiling: Time to Revise ISHLT Grading System L. Potena1, V. Agostini1, L. Borgese1, E. Rinaldi1, L. Giovannini1, J. Reeve2, M. Parkes2, M. Masetti1, A. Russo1, O. Leone1, P. Halloran2. 1Bologna University Hospital, Bologna, Italy, 2University of Alberta, Edmonton, AB, Canada
4:15 PM	(190) HLA Epitope Mismatching is Associated with Rejection and Worsened Graft Survival in Heart Transplant Recipients E. Osorio-Jaramillo1, G. W. Haasnoot2, A. Kaider3, A. Zuckermann1, A. Schaefer1, T. Haberl1, J. Goekler1, P. Angleitner1, R. Moayedifar1, G. F. Fischer4, G. Laufer1, F. H. Claas2, A. Z. Aliabadi-Zuckermann1. 1Division of Cardiac Surgery, Medical University of Vienna, Vienna, Austria, 2Department of Immunhematology and Blood Transfusion, Leiden University Medical Center, Leiden, Netherlands, 3Center for Medical Statistics, Informatics and Intelligent Systems, Medical University of Vienna, Vienna, Austria, 4Department for Blood Group Serology and Transfusion Medicine, Medical University of Vienna, Vienna, Austria
4:30 PM	(191) Non-HLA Antibodies as a Cause for Biopsy Negative Rejection: Is It Worth Testing for Them? J. A. Kobashigawa1, J. Patel1, M. Kittleson1, E. Kransdorf1, S. Dimbil1, R. Levine1, G. Esmailian1, C. Kawata1, L. Czer1, M. Hamilton1, D. Ramzy1, X. Zhang2. 1Smidt Heart Institute at Cedars-Sinai, Los Angeles, CA, 2Cedars-Sinai Medical Center, Los Angeles, CA
4:45 PM	704) Heart Transplant Patients with Histologic Normal and Molecular Microscope Abnormal Biopsies: An Exploratory Analysis K. Shah1, J. A. Kobashigawa1, J. Patel1, M. Kittleson1, D. H. Chang1, S. Dimbil1, R. Levine1, S. Sana1, L. Czer1, B. Azarbal1, F. Esmailian1, P. Halloran2. 1Cedars-Sinai Smidt Heart Institute, Los Angeles, CA, 2University of Alberta, Alberta, AB, Canada
5:00 PM	(193) Racial Differences in Risk of Acute Rejection after Cardiac Transplantation R. C. Patel1, L. B. Cooper2, R. T. Cole3, S. Sinha2, L. J. Bogar4, S. D. Barnett2, A. Cochrane2, M. Psotka2, P. Shah2. 1Virginia Commonwealth University School of Medicine, Richmond, VA, 2Department of Heart Failure and Transplant, Inova Heart and Vascular Institute, Falls Church, VA, 3Department of Heart Failure and Transplant, Emory University, Atlanta, GA, 4Department of Cardiac Surgery, Inova Heart and Vascular Institute, Falls Church, VA
5:15 PM	(194) Crossing Low Level Donor-Specific Antibody at the Time of Heart Transplantation May Save Lives J. A. Kobashigawa1, M. Kittleson1, D. H. Chang1, E. Kransdorf1, S. Dimbil1, R. Levine1, C. Kawata1, M. Olymbios1, A. Velleca1, L. Czer1, X. Zhang2, D. Ramzy1, J. Patel1. 1Cedars-Sinai Smidt Heart Institute, Los Angeles, CA, 2Cedars-Sinai Medical Center, Los Angeles, CA
5:30 PM	(195) Identification of Risk Factors for Biopsy-Proven Rejection during the First Year Post Heart Transplantation G. Coutance1, G. Bonnet2, J. Van Keer3, M. Racapé3, P. Bruneval2, J. Duong Van Huyen3, J. Taupin4, S. Varnous5, L. Lecuyer6, P. Rouvier5, X. Jouven2, A. Loupy3. 1Paris Transplant Group, Pitié-Salpêtrière Hospital, Paris, France, 2Paris Transplant Group, Hôpital Européen Georges Pompidou, Paris, France, 3Paris Transplant Group, Paris, France, 4Saint Louis Hospital, Paris, France, 5Groupe Hospitalier Pitié-Salpêtrière, Paris, France, 6Hôpital Européen Georges Pompidou, Paris, France

Visit the ISHLT2019 Online Program Viewer to see the full abstracts from this session

Junior Faculty Clinical Case Reports: Heart Failure/Transplantation (Banda Sea 1)
(HF/HTX)   Poster Numbers: 1338-1390
 

---

Visit the ISHLT2019 Online Program Viewer to see the full abstracts from this session

Junior Faculty Clinical Case Reports: Heart Failure/Transplantation (Banda Sea 2)
(HF/HTX)   Poster Numbers: 1391-1417

Visit the ISHLT2019 Online Program Viewer to see the full abstracts from this session

Primary Audience: BSTR, HTX
Secondary Audience: PATH, PEDS

Chairs: Alexander M. Bernhardt, MD and Karl B. Lemstron, MD, PhD
 

6:30 PM	(435) Survival Outcomes in Heart Transplant Patients; Specific Focus on ACHD Patients and Their Outcomes as Compared to Dilated and Ischemic Cardiomyopathy Patients A. Kinsella1, V. Rao1, C. Fan2, C. Manlhiot2, J. Stehlik2, H. Ross2, A. C. Alba2. 1Cardiac Surgery, Toronto General Hospital, Toronto, ON, Canada, 2Peter Munk Cardiac Centre, Toronto General Hospital, Toronto, ON, Canada
6:35 PM	(436) Candidate Selection and the Survival Benefit of Heart Transplantation in the United States W. F. Parker1, E. S. Huang1, R. D. Gibbons2, A. S. Anderson3, M. M. Churpek1. 1University of Chicago Medicine, Chicago, IL, 2Public Health Sciences, University of Chicago Medicine, Chicago, IL, 3Northwestern Medicine, Chicago, IL
6:40 PM	(437) Does Pre-Existing Donor Heart Coronary Artery Disease Impact Survival after Orthotopic Heart Transplantation? J. Jahanyar1, J. M. Liao2, N. Zhang3, R. J. Butterfield III4, B. W. Hardaway5, R. L. Scott5, E. D. Steidley5. 1Cardiothoracic Surgery, Mayo Clinic, Phoenix, AZ, 2Medicine, University of Washington, Seattle, WA, 3Health Sciences Research, Mayo Clinic, Phoenix, AZ, 4Biostatistics, Mayo Clinic, Phoenix, AZ, 5Cardiology, Mayo Clinic, Phoenix, AZ
6:45 PM	(438) Long-Term Survival after Heart Transplantation: Interaction between Donor and Recipient Age A. Lechiancole, S. Sponga, V. Ferrara, C. Nalli, C. Di Nora, G. Guzzi, D. Piani, M. Meneguzzi, G. Benedetti, V. Tursi, U. Livi. Cardio-Thoracic Surgery of Udine, ASUIUD, Udine, Italy
6:50 PM	(982) Heart Transplantation with ECMO Bridging: Survival Differences in the Era of the New Heart Allocation Policy J. Jahanyar1, J. M. Liao2, N. Zhang3, R. J. Butterfield III4, B. W. Hardaway5, R. L. Scott5, E. D. Steidley5. 1Cardiothoracic Surgery, Mayo Clinic, Phoenix, AZ, 2Medicine, University of Washington, Seattle, WA, 3Health Sciences Research, Mayo Clinic, Phoenix, AZ, 4Biostatistics, Mayo Clinic, Phoenix, AZ, 5Cardiology, Mayo Clinic, Phoenix, AZ
6:55 PM	(440) Survival after Primary Graft Dysfunction in Heart Transplantation: Outcomes of the National UK Data S. Avtaar Singh1, S. Das De1, S. Rushton2, N. Banner3, C. Berry4, N. Al-Attar1. 1Cardiothoracic Surgery, Golden Jubilee National Hospital, Glasgow, United Kingdom, 2Statistics, National Health Service Blood and Transplant, Bristol, United Kingdom, 3Advanced Heart Failure and Transplantation, Harefield Hospital, London, United Kingdom, 4Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom

Visit the ISHLT2019 Online Program Viewer to see the full abstracts from this session

Primary Audience: PEDS, HF
Secondary Audience: LTX

Chairs: Jennifer Conway, MD and Tomasz Zielinski, MD
 

6:30 PM	(483) Efficacy of Tafamidis in Patients with Hereditary or Wild-Type Transthyretin Amyloid Cardiomyopathy: Further Results from the ATTR-ACT Trial M. Grogan1, R. Witteles2, S. J. Shah3, J. H. Schwartz4, B. Gundapaneni5, T. A. Patterson6, M. B. Sultan4, M. S. Maurer7. 1Department of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, 2Stanford University School of Medicine, Stanford, CA, 3Division of Cardiology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, 4Pfizer Inc, New York, NY, 5Department of Cardiovascular Diseases, Syneos Health, Raleigh, NC, 6Pfizer Inc, Groton, CT, 7Columbia University College of Physicians and Surgeons, New York, NY
6:35 PM	(484) The Rising Epidemic of Resource Utilization for Adult Congenital Heart Disease-Related Heart Failure in the United States D. S. Burstein1, J. W. Rossano1, H. Griffis1, X. Zhang1, R. Fowler2, B. P. Frischhertz2, Y. Y. Kim1, J. Lindenfeld2, J. A. Mazurek3, J. N. Menachem2. 1Cardiology, Children's Hospital of Philadelphia, Philadelphia, PA, 2Cardiology, Vanderbilt University Medical Center, Nashville, TN, 3Cardiology, Hospital of University of Pennsylvania, Philadelphia, PA
6:40 PM	(970) Comparison of Long-Term Effects of Cell Therapy in Patients with Ischemic and Nonischemic Heart Failur G. Poglajen, G. Zemljic, S. Frljak, A. Cerar, M. Jaklič, B. Vrtovec. Advanced Heart Failure and Transplantation Center, University Medical Center Ljubljana, Ljubljana, Slovenia
6:45 PM	(486) Myocardial Ischemia Correlates with Left Ventricular Systolic Dysfunction in Patients with Noncompaction Cardiomyopathy A. Cerar1, M. Jaklic1, M. Dolenc Novak2, B. Guzic Salobir2, R. Zbacnik3, M. Kozelj1, B. Vrtovec1. 1Department of Cardiology, UMC Ljubljana, Ljubljana, Slovenia, 2Department of Nuclear Medicine, UMC Ljubljana, Ljubljana, Slovenia, 3Department of Radiology, UMC Ljubljana, Ljubljana, Slovenia
6:50 PM	(487) Absence of Pre-Transplant Pulmonary Features of Sarcoidosis is of Low Negative Predictive Value in End-Stage Cardiac Sarcoidosis H. K. Rokadia1, A. K. Jamil2, R. El Tomi2, H. Zafar2, T. Nisar2, M. Petrozzi1, R. L. Gottlieb1. 1Baylor University Medical Center, Dallas, TX, 2Baylor Scott & White Research Institute, Dallas, TX
6:55 PM	(488) Undiagnosed Cardiac Sarcoidosis Has a Significant First Presentation as Sudden Cardiac Death: An Autopsy Review D. Pedrotty1, A. Rosenbaum2, S. Kapa2, L. Blauwet2, J. Maleszewski3. 1Heart Failure Cardiology, University of Pennsylvania, Philadelphia, PA, 2Cardiology, Mayo Clinic, Rochester, MN, 3Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN

Visit the ISHLT2019 Online Program Viewer to see the full abstracts from this session

Primary Audience: PH, HTX

Chairs: John Granton, MD and Joanna Pepke-Zaba, MD
 

6:40 PM	(498) Association between Serial Measurements of Tricuspid Annular Plane Systolic Excursion and Mortality Post Heart Transplant J. K. Vishram-Nielsen1, F. Foroutan2, H. J. Ross2, F. Gustafsson3, T. A. Buchan2, A. Alba2. 1The Heart Centre, Rigshospitalet, University of Copenhagen, Denmark, & Ted Rogers Center for Heart Research, UHN, Toronto, ON, Canada, 2Ted Rogers Center for Heart Research, UHN, Toronto, ON, Canada, 3The Heart Centre, Rigshospitalet, University of Copenhagen, Denmark, Copenhagen, Denmark
6:45 PM	(499) Prognostic Value of Cardiac Magnetic Resonance Acquired at One Year after Heart Transplantation P. Patrizia1, O. Rimoldi2, G. Masciocco1, L. D'Angelo1, G. Foti1, G. Quattrocchi1, A. Milazzo1, R. Facchetti3, C. Giannattasio1, F. Maria1. 1Cardiothoracic and Vascular DPT, ASST Niguarda, Milan, Italy, 2CNR, IBFM, Segrate (MI), Italy, 3Health Science DPT, Bicocca University, Milan, Italy
6:50 PM	(500) Can CT Measures of Thoracic Muscle Provide Prognostication among Heart Transplant Recipients? A. J. Kuchnia1, J. Lortie1, N. Stabo2, N. Tsuchiya2, T. Hess3, N. Binkley3, C. Francois2, M. Schiebler2, J. Hermsen4, R. Dhingra3. 1Nutritional Sciences, University of Wisconsin-Madison, Madison, WI, 2Department of Radiology, University of Wisconsin-Madison, Madison, WI, 3Department of Medicine, University of Wisconsin-Madison, Madison, WI, 4Department of Surgery, University of Wisconsin-Madison, Madison, WI

Visit the ISHLT2019 Online Program Viewer to see the full details for this session

Primary Audience: HF/HTX
Secondary Audience: MCS

Session Summary: This symposium will provide an overview of the potential alternatives to and fresh ideas for organ transplantation. Each speaker will provide an overview of the “state of the art” in their respective area of organ repair, regeneration or replacement, and will give insight into successes, challenges and potential of their respective areas, incorporating discussion of the clinical feasibility, ethics and potential of the respective therapies.

Chairs: Mrinalini Krishnan, MD and Ulrich Steinseifer, MD
 

7:00 AM	Copy and Paste vs. Renovate: Cardiac 3D Printing and Its Future Direction Doris A. Taylor, PhD, FAHA, FACC, Texas Heart Institute, Houston, TX, USA
7:15 AM	‘When Pigs Fly’: Where Are We Now with Xenotransplantation? Richard Pierson, MD, Massachusetts General Hospital, Boston, MA, USA
7:30 AM	Hitting Reset: Utility of Stem Cells to Regenerate the Heart Sonja Schrepfer, MD, PhD, UCSF Medical Center, San Francisco, CA, USA
7:45 AM	15-min Panel Discussion

Visit the ISHLT2019 Online Program Viewer to see the full abstracts from this session

Primary Audience: HF/HTX
Secondary Audience: BSTR, PATH

Chairs: Yoshikatsu Saiki, MD, PhD and Evan P. Kransdorf, MD, PhD
 

10:30 AM	(217) Identification of Latent Classes of Cardiac Allograft Vasculopathy Trajectories after Heart Transplantation and Their Determinants G. Coutance1, M. Racapé2, G. Bonnet3, M. Raynaud2, J. Van Keer2, M. Bories3, P. Bruneval3, J. Duong Van Huyen4, J. Taupin5, S. Varnous6, R. Guillemain7, X. Jouven3, A. Loupy4. 1Paris Transplant Group, Pitié-Salpêtrière Hospital, Paris, France, 2Paris Transplant Group, Paris, France, 3Paris Transplant Group, Hôpital Européen Georges Pompidou, Paris, France, 4Paris Transplant Group, Necker Hospital, Paris, France, 5Saint Louis Hospital, Paris, France, 6Pitié-Salpêtrière Hospital, Paris, France, 7Hôpital Européen Georges Pompidou, Paris, France
10:45 AM	(218) Leukotriene B4 Contributes to Development of Cardiac Allograft Vasculopathy K. K. Khush1, D. Wang2, G. Tediashvili2, H. Luikart1, N. D'Emilio1, Y. Moayedi1, S. Schrepfer2. 1Stanford University, Stanford, CA, 2University of California San Francisco, San Francisco, CA
11:00 AM	(219) Novel Descriptors of Coronary Wall Properties Measured by OCT at Baseline Are Associated with CAV-Related Intimal Thickening One Year after Heart Transplant Z. Chen1, M. Pazdernik2, A. Wahle1, H. Zhang1, V. Melenovsky2, J. Kautzner2, V. Karmazin2, H. Bedanova3, A. Tomasek3, E. Ozabalova3, M. Sonka1. 1University of Iowa, Iowa City, IA, 2Institute of Clinical and Experimental Medicine (IKEM), Prague, Czech Republic, 3Cardiovascular and Transplantation Surgery Center, St. Annes University Hospital and Masaryk University Brno, Brno, Czech Republic
11:15 AM	(220) Low Serum Magnesium is Associated with Increased Mortality and Cardiac Allograft Vasculopathy Following Heart Transplantation Y. Peled1, J. Lavee1, N. Shlomo2, T. Cohen2, A. Kogan1, E. Maor1, M. Shechter1, D. Freimark1, R. Klempfner1. 1Sheba Medical Center Tel Hashomer and Tel-Aviv University, Ramat Gan, Israel, 2Israeli Association for Cardiovascular Trials, Ramat Gan, Israel
11:30 AM	(221) Increased Platelet Aggregation in Heart Transplant Recipients with Cardiac Allograft Vasculopathy K. P. Bjerre1, K. Berg1, T. S. Clemmensen2, S. H. Poulsen1, S. D. Kristensen1, A. Hvas1, E. L. Grove1, H. Eiskjær1. 1Aarhus University Hospital, Aarhus N, Denmark, 2Horsens Regional Hospital, Horsens, Denmark
11:45 AM	(222) Mild Acute Cellular Rejection is Not Associated with Development of Cardiac Allograft Vasculopathy Assessed by Intravascular Ultrasound and Coronary Angiography in Heart Transplant Recipients - A Substudy of the SCHEDULE Trial L. M. Nelson1, A. K. Andreassen2, S. Arora2, B. Andersson3, E. Gude2, H. Eiskjær4, G. Rådegran5, G. Dellgren6, L. Gullestad7, F. Gustafsson1. 1Department of Cardiology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark, 2Department of Cardiology, Oslo University Hospital, Rikshospitalet, Oslo, Norway, 3Department of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden, 4Department of Cardiology, Aarhus University Hospital, Skejby, Aarhus, Denmark, 5The Clinic for Heart Failure and Valvular Disease, Skåne University Hospital and Lund University, Lund, Sweden, 6Transplant Institute, Sahlgrenska University Hospital, Gothenburg, Sweden, 7Department of Cardiology, Oslo University Hospital, Rikshospitalet, and University of Oslo, Oslo, Norway
12:00 PM	(223) Are Gene Expression Profile Testing Scores Associated with New Onset Cardiac Allograft Vasculopathy? A. Lala1, D. Hiller2, J. Yee2, K. Khush3, R. Alharethi4, S. Pinney5. 1Medicine, Cardiology, Population Health Science, Icahn School of Medicine at Mount Sinai, Mount Sinai Hospital, New York, NY, 2CareDx, Brisbane, CA, 3Stanford University School of Medicine, Stanford, CA, 4University of Utah School of Medicine, Salt Lake City, UT, 5Medicine, Cardiology, Icahn School of Medicine at Mount Sinai, Mount Sinai Hospital, New York, NY

Visit the ISHLT2019 Online Program Viewer to see the full details for this session

Primary Audience: HF/HTX

Session Summary: In collaboration with the Society for Cardiovascular Magnetic Resonance (SCMR), this symposium will address how CMR advances in structural and functional imaging techniques have led to better cardiac tissue and anatomical characterization in complex patients. We will address its clinical role in the management of cardiomyopathies and heart transplant and explore pathological and imaging relationships while addressing standard and novel CMR based diagnostic approaches including contrast free imaging and imaging in patients with pacemakers.

Chairs: Daniel Kim, MD and Sonya Babu-Narayan, MBBS, BSc, PhD
 

10:30 AM	MRI Sequences and Pathologic Correlates: The First Face of Janus Annalisa Angelini, MD, University of Padua, Padua, Italy
10:45 AM	MRI Sequences and Pathologic Correlates: The Second Face of Janus Timothy C. Wong, MD, MS, University of Pittsburg, Pittsburg, PA, USA
11:00 AM	Q&A
11:05 AM	CMR and Cardiomyopathies: A World Beyond Speckles Victor A. Ferrari, MD, Perelman School of Medicine, Philadelphia, PA, USA
11:20 AM	CASE PRESENTATION: A Post-Transplant Patient with New Worsening of LV Function Mandar Aras, MD, UCSF Medical Center, San Francisco, CA, USA
11:25 AM	CMR and Heart Transplantation: One Stop Shop? Sofia C. Masri, MD, University of Washington, Seattle, WA, USA
11:40 AM	CASE PRESENTATION: Patient with CHD and New Echocardiographic Findings: What Next? Chesney Castleberry, MD, Washington University in St. Louis, St. Louis, MO, USA
11:45 AM	CMR and Congenital Heart Disease: Not as Baffling as You Thought Sonya Babu-Narayan, MBBS, BSc, PhD, Imperial College London, London, UK
12:00 PM	15-min Panel Discussion

Visit the ISHLT2019 Online Program Viewer to see the full abstracts from this session

Primary Audience: HF/HTX
Secondary Audience: MCS

Chairs: Sung-Ho Jung, MD and Marian Urban, MD
 

2:00 PM	(245) LVAD Patients with RV Failure Pre-Heart Transplant Have Reduced Post-Transplant Survival Y. D. Barac, O. Jawitz, J. Schroder, M. Daneshmand, C. Patel, C. Milano. Duke University Medical Center, Durham, NC
2:15 PM	(246) Predictors of Favorable Outcome in Patients Bridged to Transplant with Temporary Mechanical Circulatory Support Devices M. Yin1, O. Wever-Pinzon1, M. R. Mehra2, C. G. Selzman3, A. E. Toll4, W. S. Cherikh4, J. Nativi-Nicolau1, J. C. Fang1, A. G. Kfoury5, E. M. Gilbert1, L. Kemeyou1, S. H. McKellar3, A. Koliopolou3, M. Vaduganathan2, S. Drakos1, J. Stehlik1. 1Cardiovascular Services, University of Utah, Salt Lake City, UT, 2Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA, 3Cardiothoracic Surgery, University of Utah, Salt Lake City, UT, 4United Network for Organ Sharing, Richmond, VA, 5Intermountain Healthcare, Salt Lake City, UT
2:30 PM	(247) In Hospital Outcomes in Adult Congenital Heart Disease Patients with Fontan Undergoing Heart Transplantation - A Decade Nationwide Analysis from 2004 until 2014 G. A. Hernandez1, A. Lemor2, D. Clark3, V. Blumer1, R. Byrne3, R. Fowler3, E. Sandhaus3, A. Weingarten3, B. Frischhertz3, K. Schlendorf3, S. Zalawadiya3, J. Lindenfeld3, J. Menachem3. 1University of Miami, Miami, FL, 2Henry Ford Hospital, Detroit, MI, 3Vanderbilt University, Nashville, TN
2:45 PM	(248) Development and Validation of a Risk Model for Primary Graft Failure after Heart Transplantation and Comparison to the RADIAL Risk Score D. Reichart1, L. Castro2, N. Ruebsamen1, S. Blankenberg1, H. Reichenspurner2, A. Bernhardt2. 1Department of Cardiology, University Heart Center Hamburg, Hamburg, Germany, 2Department of Cardiovascular Surgery, University Heart Center Hamburg, Hamburg, Germany
3:00 PM	(249) Outcomes with Heartsize Matching among Cardiac Transplant Recipients with Pulmonary Hypertension M. Shah1, O. Saeed1, J. Shin1, S. Murthy1, D. B. Sims1, S. Vukelic1, D. Goldstein2, S. J. Forest2, U. P. Jorde1, S. R. Patel1. 1Advanced HF/Transplant Cardiology, Montefiore Medical Center, Bronx, NY, 2Cardiovascular and Thoracic Surgery, Montefiore Medical Center, Bronx, NY
3:15 PM	(250) Insights from High-Performing Heart Transplant Centers across the Recipient Risk-Spectrum T. P. Singh1, M. R. Mehra2, K. Gauvreau3. 1Pediatrics, Harvard Medical School, Boston, MA, 2Medicine, Harvard Medical School, Boston, MA, 3Biostatistics, Harvard School of Public Health, Boston, MA
3:30 PM	(251) A Direct Heart-Transplantation Strategy in Selected Patients on Extra-Corporeal Membrane Oxygenation Achieved Favorable Post-Transplant Outcomes G. Coutance1, G. Lebreton1, N. Jacob1, N. Br´chot2, P. Demondion1, A. Bouglé3, L. Nguyen1, S. Varnous1, A. Combes2, P. Leprince1. 1Cardiac Surgery, Groupe Hospitalier Pitié-Salpêtrière, Paris, France, 2Intensive Care Unit, Groupe Hospitalier Pitié-Salpêtrière, Paris, France, 3Anaesthesiology, Groupe Hospitalier Pitié-Salpêtrière, Paris, France

Visit the ISHLT2019 Online Program Viewer to see the full details for this session

Primary Audience: HF/HTX
Secondary Audience: LF/LTX

Session Summary: The paucity of donors is still the primary limitation for heart transplantation across the world. Too many donor hearts are not accepted for concerns over particular risk factors. This symposium will explore novel ways to expand the donor pool. In a time when the waiting lists grow exponentially, our field must find ways to maximize donor utilization.

Chairs: Kiran K. Khush, MD and James K. Kirklin, MD
 

4:15 PM	Perfect is the Enemy of Good: Using Marginal Donor Hearts David Rabkin, MD, Loma Linda University, Loma Linda, CA, USA
4:30 PM	Riding the Epidemic: Hepatitis C + Donors Should Become Standard of Care Kelly Schlendorf, MD, Vanderbilt University, Nashville, TN, USA
4:45 PM	Distance Makes the Heart Grow Fonder: Miles Should Not Limit Donor Acceptance Christopher Hayward, MD, St Vincent's Hospital, Sydney, Australia
5:00 PM	Love It or Levophed It: High Dose Catecholamine Donor Support and Outcomes After Heart Transplantation Andreas Zuckermann, MD, Medical University of Vienna, Vienna, Austria
5:15 PM	DEBATE: All Nations Should Have an Opt Out System (PRO) Maria Dolores Cosio, MD, Hospital 12 Octubre, Madrid, Spain
5:30 PM	DEBATE: All Nations Should Have an Opt Out System (CON) Peter J. Bergin, MBBS, FRACP, Alfred Hospital, Melbourne, Australia
5:45 PM	15-min Panel Discussion

Visit the ISHLT2019 Online Program Viewer to see the full abstracts from this session

Heart Failure/Transplantation (Adult) (Hibiscus 1)
(HF/HTX)   Poster Numbers: 981-1013
 

---

Visit the ISHLT2019 Online Program Viewer to see the full abstracts from this session

Heart Failure/Transplantation (Adult) (Hibiscus 2)
(HF/HTX)   Poster Numbers: 944-978

Visit the ISHLT2019 Online Program Viewer to see the full abstracts from this session

Primary Audience: HF/HTX
Secondary Audience: PHARM

Chairs: Rami Alharethi, MD and Hye Won Lee, PhD
 

6:15 PM	(501) Risk Stratification of Inotropic Therapy for Heart Transplant Candidates in the Era of Ventricular Assist Device Support L. K. Truby1, V. K. Topkara2, S. D. Russell1, C. B. Patel1, R. Agarwal1. 1Duke University Medical Center, Durham, NC, 2Columbia University Medical Center, New York, NY
6:20 PM	(502) Mechanical Circulatory Support Patients Awaiting Heart Transplant with Positive AT1R Antibodies Have Acceptable Outcome Post-Heart Transplant D. H. Chang, J. Patel, M. Kittleson, D. Geft, S. Dimbil, R. Levine, C. Kawata, L. Czer, J. Moriguchi, D. Ramzy, J. A. Kobashigawa. Cedars-Sinai Smidt Heart Institute, Los Angeles, CA
6:25 PM	(503) Predictors and Clinical Outcomes of Vasoplegia in Patients Bridged to Heart Transplantation with Continuous Flow Left Ventricular Assist Devices R. Asleh, H. Alnsasra, S. D. Schettle, R. Taher, S. M. Dunlay, J. M. Stulak, R. C. Daly, A. Behfar, N. L. Pereira, A. L. Clavell, S. Multais, R. P. Frantz, S. S. Kushwaha. Department of Cardiovascular Diseases, Mayo Clinic, Rochester, MN
6:30 PM	(504) Elevated Pre-Transplant Neutrophil to Lymphocyte Ratio is Associated with Increased Vasoplegia Syndrome in Cardiac Transplantation N. Ahmed, H. Gandhi, K. Rahgozar, S. Guo, E. Sun, O. Saeed, S. Patel, S. Murthy, J. J. Shin, S. Vukelic, S. Forest, D. J. Goldstein, U. P. Jorde, D. B. Sims. Montefiore Medical Center Albert Einstein College of Medicine, Bronx, NY
6:35 PM	(505) Utility of Routine versus Triggered Evaluations of Rejection Greater Than Two Years Following Heart Transplant J. R. Golbus, M. C. Konerman, K. D. Aaronson. Internal Medicine, University of Michigan, Ann Arbor, MI
6:40 PM	(506) Protocol Endomyocardial Biopsy beyond Six Months - It's Time to Move On K. Oh1, M. H. Mustehsan1, D. B. Sims1, O. Saeed1, S. Vukelic1, J. J. Shin1, S. Murthy1, A. Luke1, S. J. Forest2, D. Goldstein2, U. Jorde1, S. R. Patel1. 1Medicine, Division of Cardiology, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY, 2Cardiovascular and Thoracic Surgery, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY
6:45 PM	(507) Clinical Utility of the IMPACT Score for Mortality Prediction after Heart Transplantation: External Validation Study C. D. Ortiz Bautista1, J. Muniz Garcia2, F. Gonzalez-Vilchez3, J. Segovia Cubero4, M. G. Crespo Leiro5, R. Lopez Vilella6, J. Gonzalez Costelo7, E. Roig Minguel8, J. M. Arizon Del Prado9, J. M. Sobrino Marquez10, I. P. Garrido Bravo11, J. F. Delgado Jimenez12. 1Cardiology, Hospital General Universitario Gregorio Marañón, Madrid, Spain, 2Instituto de Investigaci&ocaute;n Biomédica (INIBIC), Complexo Hospitalario Universitario de A Coruña, A Coruña, Spain, 3Cardiology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, 4Cardiology, Hospital Universitario Puerta de Hierro, Madrid, Spain, 5Cardiology, Complexo Hospitalario Universitario de A Coruña, A Coruña, Spain, 6Cardiology, Hospital Universitario La Fe, Valencia, Spain, 7Cardiology, Hospital Universitario de Bellvitge, Barcelona, Spain, 8Cardiology, Hospital Santa Creu i Sant Pau, Barcelona, Spain, 9Cardiology, Hospital Universitario Reina Sofía, Córdoba, Spain, 10Cardiology, Hospital Universitario Virgen del Rocío, Sevilla, Spain, 11Cardiology, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain, 12Cardiology, Hospital Universitario 12 de Octubre, Madrid, Spain
6:50 PM	(508) One but Not the Same: Risk Factors for Early Post-Transplant Mortality Differ between Medically Managed Patients and Those Bridged to Transplant with Left Ventricular Assist Devices L. K. Truby1, M. Farr2, V. K. Topkara2. 1Duke University Medical Center, Durham, NC, 2Columbia University Medical Center, New York, NY
6:55 PM	(509) Cardiac Transplantation across Preformed HLA-Antibody Barriers: Results of a Peritransplant Desensitization Protocol F. Ius1, S. V. Rojas1, T. Kaufeld1, W. Sommer1, C. Bara1, J. Salman1, T. Siemeni1, R. Poyanmehr1, D. Bobylev1, M. Avsar1, I. Tudorache1, C. S. Falk2, A. Haverich1, G. Warnecke1. 1Department of Cardiothoracic, Transplant and Vascular Surgery, Hannover Medical School, Hannover, Germany, 2Institute of Transplant Immunology, Hannover Medical School, Hannover, Germany
7:00 PM	(510) Treatment of Therapy-Resistant Hyperlipidaemia after Heart Transplant with PCSK9-Inhibitors K. Uyanik-Uenal1, M. Stoegerer-Lanzenberger2, K. Auersperg1, A. Aliabadi-Zuckermann1, G. Laufer1, A. Zuckermann1. 1Department of Cardiac Surgery, Medical University of Vienna (AKH), Vienna, Austria, 23rd Medical Department for Metabolic Disorders and Nephrology, Hospital Hietzing, Vienna, Austria
7:05 PM	(511) Change in Health-Related Quality of Life from Before to Early after Surgery: Findings from the Sustaining Quality of Life of the Aged: Transplant or Mechanical Support (SUSTAIN-IT) Study K. L. Grady1, A. Kao2, M. Dew3, R. Kormos4, A. Andrei1, H. Adam1, Y. Xu1, D. Pham1, L. Pollan1, C. Yancy5, E. Hsich6, W. Cotts7, S. LaRue8, M. Petty9, S. V. Pamboukian10, F. Pagani11, B. Lampert12, M. Johnson13, M. Murray1, K. Tekeda14, M. Yuzefpolskaya15, S. Silvestry16, J. Kirklin17, S. Collum1, J. Spertus2. 1Surgery / Cardiac Surgery, Northwestern University, Chicago, IL, 2Medicine, University of Missouri - Kansas City, Kansas City, MO, 3Psychiatry, University of Pittsburgh, Pittsburgh, PA, 4Cardiothoracic Surgery, University of Pittsburgh, Pittsburgh, PA, 5Medicine, Northwestern University, Chicago, IL, 6Medicine, Cleveland Clinic, Cleveland, OH, 7Medicine, Advocate Christ Medical Center, Oak Lawn, IL, 8Medicine, Washington University, St. Louis, MO, 9Surgery, University of Minnesota Medical Center, Minneapolis, MN, 10Medicine, University of Alabama, Birmingham, AL, 11Surgery, University of Michigan, Ann Arbor, MI, 12Medicine, Ohio State University, Columbus, OH, 13Medicine, University of Wisconsin, Madison, WI, 14Surgery, Columbia University, New York, NY, 15Medicine, Columbia University, New York, NY, 16Surgery, Florida Hospital, Maitland, FL, 17Surgery, University of Alabama - Birmingham, Birmingham, AL
7:10 PM	(512) Intraoperative Perfusion Strategies during Heart Transplantation: Are We Optimizing Renal Protection? N. M. Foley, M. Kuzemchak, Y. Tipograf, C. White-Dzuro, K. Balsara, K. Schlendorf, M. Danter, A. Shah. Cardiac Surgery, Vanderbilt University Medical Center, Nashville, TN

Visit the ISHLT2019 Online Program Viewer to see the full abstracts from this session

Primary Audience: HF/HTX
Secondary Audience: NHSAH

Chairs: Alejandro M. F. Bertolotti, Sr., MD and Van N. Selby, MD
 

6:15 PM	(513) Heart Transplantation for Cardiac Amyloidosis - Worthwhile? J. Patel, M. Kittleson, R. Levine, S. Sana, A. Shen, D. Geft, B. Azarbal, E. Kransdorf, J. Kobashigawa. Smidt Heart Institute at Cedars-Sinai, Los Angeles, CA
6:20 PM	(514) Contemporary Outcomes in Patients with Cardiac Amyloidosis Undergoing Heart Transplantation K. Alexander1, C. Barrett2, K. Dobos1, P. Cheng1, R. Liao1, M. Wheeler1, M. Liedtke1, D. Weisshaar3, R. Witteles1. 1Stanford University Medical Center, Stanford, CA, 2University of Colorado, Aurora, CO, 3Kaiser Permanente Santa Clara Medical Center, Santa Clara, CA
6:25 PM	(515) The Evolving Long-Term Outcome of Heart Transplantation in Amyloid Patients J. Patel, M. Kittleson, D. H. Chang, R. Cole, R. Levine, S. Dimbil, A. Jain, B. Kearney, L. Czer, A. Hage, F. Esmailian, J. A. Kobashigawa. Cedars-Sinai Smidt Heart Institute, Los Angeles, CA
6:30 PM	(979) Heart Transplantation in Cardiac Amyloidosis: A Ten Year Experience J. P. Donnelly1, E. G. Soltesz2, M. Z. Tong2, S. A. Hall3, P. Kale3, J. D. Estep1, M. Hanna1. 1Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, OH, 2Thoracic and Cardiovascular Surgery, Cleveland Clinic Foundation, Cleveland, OH, 3Annette C. and Harold C. Simmons Transplant Institute, Baylor Scott & White Research Institute, Dallas, TX
6:35 PM	(516) Differential Gene Expression by Race and Impact on Risk after Heart Transplantation Y. Moayedi1, C. S. Fan2, R. J. Miller3, D. Hillier4, M. Tremblay-Gravel1, M. A. Shullo5, R. Woodward4, J. Yee4, C. Manlhiot6, S. Pinney7, S. A. Hall8, K. K. Khush9, H. J. Ross10, J. J. Teuteberg9. 1Medicine, Stanford University, Stanford, CA, 2Biostatistics and Epidemiology, University Health Network , University of Toronto, University of Toronto, ON, Canada, 3Medicine, Division of Cardiology, Stanford University, Palo Alto, CA, 4CareDx, CareDx, Brisbane, CA, 5Pharmacy, West Virginia University, Morgantown, WV, 6Biostatistics, University Health Network , University of Toronto, Toronto, ON, Canada, 7Medicine, Division of Cardiology, Mount Sinai New York, NYC, NY, 8Medicine, Division of Cardiology, Baylor Health Care, Dallas, TX, 9Medicine, Division of Cardiology, Stanford University, Stanford, CA, 10Medicine, Division of Cardiology, University Health Network , University of Toronto, Toronto, ON, Canada
6:40 PM	(517) Comparison of Patients Undergoing Multiorgan Transplantation with or without Prior Ventricular Assist Device M. E. Currie1, D. Banerjee2, Y. Shudo1, B. Lingala1, Y. Zhu1, F. Haddad2, J. Woo1. 1Cardiothoracic Surgery, Stanford University, Stanford, CA, 2Medicine, Stanford University, Stanford, CA
6:45 PM	(518) 10-Year Outcomes in Heart-Kidney Transplant Patients: Is There a Protective Effect for the Donor Heart? L. Czer, M. Kittleson, J. Patel, E. Kransdorf, R. Levine, S. Dimbil, R. Sharoff, B. Kearney, D. H. Chang, M. Hamilton, F. Esmailian, J. A. Kobashigawa. Cedars-Sinai Smidt Heart Institute, Los Angeles, CA
6:50 PM	(520) Improving Nutrition Practices for Critically Ill Postoperative Heart Transplant and Ventricular Assist Device Implant Patients R. Modir1, V. Rao2, J. Teuteberg3, D. Banerjee3, P. Oyer4, Z. Tulu5, E. Hadhazy6, W. Hiesinger4, S. Jimenez3, L. Tu1, C. Hill2. 1Heart Transplant/Clinical Nutrition, Stanford University Hospital, Stanford, CA, 2Anesthesia - Cardiac, Stanford University Hospital, Stanford, CA, 3Cardiovascular Medicine, Stanford University Hospital, Stanford, CA, 4Cardiothoracic Surgery - Adult Cardiac Surgery, Stanford University Hospital, Stanford, CA, 5Solid Organ Transplant, Stanford Health Care, Stanford, CA, 6Stanford Health Care, Stanford, CA
6:55 PM	(521) The BRIGHT Study Shows Geographical Disparities in Body Mass Index among Heart Transplant Recipients M. Alrawashdeh1, M. R. Molina2, S. Beckmann3, K. Denhaerynck3, F. Dobbels4, S. De Geest3. 1Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA, 2Hospital of the University of Pennsylvania, Philadelphia, PA, 3Institute of Nursing Science, University of Basel, Basel, Switzerland, 4Department of Public Health and Primary Care, KU Leuven, Leuven, Belgium
7:00 PM	(522) Weight Gain Post Heart Transplantation is Associated with an Increased Risk for Allograft Vasculopathy and Rejection Y. Peled, D. Freimark, E. Nachum, M. Arad, D. Elian, Y. Kassif, N. Shlomo, R. Klempfner, J. Lavee. Sheba Medical Center Tel Hashomer and Tel-Aviv University, Ramat Gan, Israel
7:05 PM	(523) The Gift That Keeps on Giving? The Impact of Donor Coronary Atherosclerosis on the Development of Coronary Allograft Vasculopathy by IVUS Y. Moayedi1, C. S. Fan2, R. J. Miller3, M. Tremblay-Gravel3, M. Kawana3, H. I. Luikart1, N. D'Emilio3, J. Gordon3, J. T. Parizo3, G. Oro3, R. Wainwright3, W. Hiesinger4, C. Manlhiot2, H. J. Ross5, K. K. Khush3, J. J. Teuteberg3. 1Medicine, Stanford University, Stanford, CA, 2Biostatistics, University Health Network, University of Toronto, Toronto, ON, Canada, 3Medicine, Division of Cardiology, Stanford University, Stanford, CA, 4Cardiovascular Surgery, Stanford University, Stanford, CA, 5Medicine, Division of Cardiology, University Health Network, University of Toronto, Toronto, ON, Canada
7:10 PM	(524) Induction with Rabbit-Thymoglobulin (r-ATG) is Associated with Lower Cardiac Allograft Vasculopathy (CAV) S. Madan, S. R. Patel, O. Saeed, S. Forest, W. A. Jakobleff, J. J. Shin, D. B. Sims, D. J. Goldstein, U. P. Jorde. Montefiore Medical Center, Bronx, NY

Visit the ISHLT2019 Online Program Viewer to see the full details for this session

Primary Audience: HF/HTX
Secondary Audience: PHARM

Session Summary: Immunosuppression management balances the risks of under-immunosuppression and allograft rejection with the risks of over-immunosuppression and infection. Recent studies have demonstrated the efficacy of tacrolimus monotherapy, the utility of gene-expression profiling and the T-cell immune monitoring assay for minimization of immunosuppression. This symposium will serve to review approaches to minimization of immunosuppression as well as the pros and cons.

Chairs: Christina Aquilante, PharmD and Douglas Greig, MD
 

7:00 AM	The ABCs of Immunosuppression: Patient Profiles and Personalized Therapy Eugene DePasquale, MD, UCLA Medical Center, Los Angeles, CA, USA
7:15 AM	The Nuts and Bolts of Tailoring Immunosuppression: Impact on Long-Term Issues in Heart Transplantation Marisa G. Crespo-Leiro, MD, Hospital University A Coruña, La Coruña, Spain
7:30 AM	Minimizing Immunosuppression: Do All Roads Lead Home? Satish Arora, MD, Oslo University Hospital, Oslo, Norway
7:45 AM	15-min Panel Discussion

Visit the ISHLT2019 Online Program Viewer to see the full details for this session

Primary Audience: HF/HTX

Session Summary: This symposium will focus on changing disease epidemiology and outcomes; role of noninvasive surveillance, particularly novel approaches such as PET; advanced coronary imaging for early CAV including intracoronary imaging, plaque characterization and intracoronary haemodynamics; pharmacologic therapy including mTORi and non-immune based strategies such as antiplatelet and lipid lowering therapies, and end with a captivating debate on the role of revascularization and defibrillators for CAV treatment.

Chairs: Kyung-Hee Kim, MD, PhD and Stephan Ensminger, MD, DPhil
 

10:15 AM	Shifting CAV Landscape: Definitions, Epidemiology, and Pathophysiology Michael Pham, MD, California Pacific Medical Center, San Francisco, CA, USA
10:30 AM	Resisting Invasion: Traditional and Novel Non-Invasive Imaging Surveillance for CAV Sharon Chih, MBBS, PhD, University of Ottawa Heart Institute, Ottawa, ON, Canada
10:45 AM	New Tricks for an Old Dog: Intracoronary Imaging and Hemodynamics - A New Classification for CAV? Tor S. Clemmensen, MD, Aarhus University Hospital, Skejby, Denmark
11:00 AM	If I Knew Then What I Know Now: Old and New Drugs for CAV Prevention and Regression Yael Peled, MD, Sheba Medical Center, Tel Hashomer, Israel
11:15 AM	CASE PRESENTATION: Young Man s/p AMR Treatment Who Later Died Suddenly - What Should Have Been Done? Livia Goldraich, MD, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil
11:20 AM	DEBATE: Preventing the Invasion of the Body Snatchers: All Patients with CAV Should Have Revascularization and Defibrillators (PRO) Howard Eisen, MD, Pennsylvania College of Medicine, Hershey, PA, USA
11:35 AM	DEBATE: Preventing the Invasion of the Body Snatchers: All Patients with CAV Should Have Revascularization and ICDs (CON) Mandeep Mehra, MD, FRCP, FACC, FESC, Brigham and Women's Hospital, Boston, MA, USA
12:00 PM	10-min Panel Discussion

Visit the ISHLT2019 Online Program Viewer to see the full abstracts from this session

Primary Audience: HF/HTX

Chairs: Jorge Silva Enciso, MD and Maria A. Castel, MD, PhD
 

12:15 PM	(322) PH in Heart Transplant (HT) Candidates: Don’t Look at Ghosts, Search the Evil in the Details M. Masetti, A. Moretta, A. Russo, F. Dardi, M. Palazzini, S. Martin Suarez, A. Loforte, F. Grigioni, N. Galiè, L. Potena. Cardiovascular Department, Bologna University Hospital, Bologna, Italy
12:30 PM	(323) Ratio of Systolic Blood Pressure to Pulmonary Capillary Wedge Pressure Ratio: A Novel Prognostic Marker in Chronic Heart Failure N. Narang, T. Imamura, J. E. Blair, L. Holzhauser, I. Ebong, M. N. Belkin, A. Kanelidis, A. Oehler, D. Yu, T. Fujino, D. Nitta, B. Chung, A. Nguyen, B. A. Smith, J. Raikhelkar, N. Sarswat, G. H. Kim, V. Jeevanandam, G. Sayer, N. Uriel. University of Chicago Medical Center, Chicago, IL
12:45 PM	(324) Association between Central Hemodynamics and Glomerular Filtration Rate in Patients with Advanced Heart Failure E. Bobbio1, S. Esmaily2, E. Bollano3, S. Bartfay3, P. Dahlberg3, G. Dellgren4, K. Karason3. 1Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenbug, Sweden, 2Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, 3Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden, 4Transplantation, Sahlgrenska University Hospital, Gothenburg, Sweden
1:00 PM	(325) Use of Remote Dielectric Sensing (ReDS) as Point-of-Care Testing Following Heart Failure Hospitalization and Risk of 30-Day Readmission M. H. Barghash1, A. Lala1, G. Giustino1, A. Parikh1, J. Ullman1, S. S. Mitter1, S. Konje2, B. Keith1, N. Moss1, D. Mancini1, M. G. Trivieri1, J. Contreras1, D. Burkhoff3, S. P. Pinney1. 1The Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai Hospital, New York, NY, 2Department of Medicine, Mount Sinai Hospital, New York, NY, 3Department of Medicine, Division of Cardiology, Columbia University Medical Center, New York, NY
1:15 PM	(326) Lung Ultrasound May Reduce Heart Failure Hospitalizations: Preliminary Results from the LUS-HF Trial M. Rivas-Lasarte1, A. Maestro-Benedicto1, J. Fernandez-Martinez1, J. Álvarez-García1, E. Solé-González1, L. López-López2, S. Mirabet-Perez2, V. Brossa-Loidi2, A. Sionis1, J. Cinca1, E. Roig2. 1Cardology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, 2Cardiology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
1:30 PM	(327) Cardiac Autonomic Nerves Stimulation Improves Hemodynamics: A Pilot Study in Advanced Heart Failure Patients T. Diaz1, C. Marin y Kall2, J. Boehmer3, M. Cowie4, A. Mebazaa5, M. Cuchiara6. 1Pacífica Salud Hospital Punta Pacífica, Panama City, Panama, 2International Medicine Institute, University of Miami, Miami, FL, 3Penn State Hershey Heart and Vascular Institute, Hershey, PA, 4National Heart and Lung Institute, Imperial College London, London, United Kingdom, 5University Paris Diderot, Paris, France, 6NeuroTronik Inc, Durham, NC
1:45 PM	(328) Cell Therapy is Associated with Reduction of Functional Mitral Regurgitation in Cardiomyopathy Patients with High End-Diastolic Volumes S. Frljak1, G. Zemljic1, G. Poglajen1, A. Cerar1, M. Jaklic1, F. Haddad2, B. Vrtovec1. 1Advanced Heart Failure and Transplantation Center, UMC Ljubljana, Ljubljana, Slovenia, 2Stanford Cardiovascular Institute, Stanford, CA

Visit the ISHLT2019 Online Program Viewer to see the full abstracts from this session

Primary Audience: HF/HTX
Secondary Audience: PATH

Chairs: Eugene C. DePasquale, MD and Marta Farrero Torres, MD, PhD
 

12:15 PM	(329) End Stage Renal Disease after Cardiac Transplantation: An 11-Year National Cohort Study M. Kosztowski, J. M. Garonzik-Wang, A. Massie, R. S. Higgins, D. L. Segev, A. Kilic. Department of Surgery, Johns Hopkins, Baltimore, MD
12:30 PM	(330) HLA-G 14BP Polymorphism Matching Protects against Development of Post-Transplant Malignancy Following Heart Transplantation M. B. Adamson1, R. V. Ribeiro1, F. Yu1, J. Lazarte1, K. Runeckles2, C. Manlhiot2, V. Rao1, D. Delgado1. 1Peter Munk Cardiac Centre, Toronto, ON, Canada, 2The Hospital for Sick Children, Toronto, ON, Canada
12:45 PM	(331) The Impact of New Onset Post-Transplant Diabetes on Outcomes after Heart Transplantation A. R. Vest1, W. S. Cherikh2, S. M. Noreen2, J. Stehlik3, K. K. Khush4. 1Tufts Medical Center, Boston, MA, 2United Network for Organ Sharing (UNOS), Richmond, VA, 3University of Utah, Salt Lake City, UT, 4Stanford University, Stanford, CA
1:00 PM	(332) Severe Acute Kidney Injury after Cardiac Transplantation is a Marker of Poor Early Outcome and Impacts on Late Renal Function - A UK Cohort Study L. Wang1, T. Wang2, S. N. Rushton3, A. J. Fisher1, N. S. Sheerin4, J. H. Dark1. 1Cardiothoracic Services, Freeman Hospital, Newcastle upon Tyne, United Kingdom, 2Univeristy College London, London, United Kingdom, 3Statistics and Clinical Studies, National Health Service Blood and Transplant, Bristol, United Kingdom, 4Renal Services, Freeman Hospital, Newcastle upon Tyne, United Kingdom
1:15 PM	(333) The Impact of Complement-Binding Donor-Specific Antibodies on Adverse Events Long-Term after Heart Transplantation J. A. Kobashigawa, M. Kittleson, D. H. Chang, E. Kransdorf, R. Levine, S. Dimbil, C. Kawata, M. Olymbios, A. Velleca, L. Czer, X. Zhang, J. Chung, J. Patel. Cedars-Sinai Smidt Heart Institute, Los Angeles, CA
1:30 PM	(439) Heart Transplantation Survival and the Use of Traumatically Brain-Injured Donors Y. D. Barac, O. Jawitz, J. Klapper, J. Schroder, M. Daneshmand, C. Patel, C. Milano, M. Hartwig. Duke University Medical Center, Durham, NC
1:45 PM	(335) Association between AT1R Autoantibody with Adverse Outcomes in Patients Bridged to Heart Transplant Using Continuous Flow Ventricular Assist Device V. Q. Chau1, K. Nicholson1, M. Flattery1, F. McDougan2, K. Desai1, P. Uber1, G. Gupta3, P. Kimball2, K. B. Shah1. 1Division of Cardiology and Pauley Heart Center, Virginia Commonwealth University, Richmond, VA, 2Division of Transplant Surgery, Virginia Commonwealth University, Richmond, VA, 3Division of Transplant Nephrology, Virginia Commonwealth University, Richmond, VA